ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.–(BUSINESS WIRE)– ImmunoGen,
Inc. (Nasdaq: IMGN), a leader in the expanding field of
antibody-drug conjugates (ADCs) for the treatment of cancer, today
announced that the following presentations by Company management at
upcoming investor conferences will be webcast:

• Canaccord Genuity Growth Conference
  1:30pm ET, August 10,
  2016

• Morgan Stanley Global Healthcare Conference
  2:50pm ET,
  September 12, 2016

The webcasts will be accessible live through the “Investors” section of
the Company’s website, www.immunogen.com;
a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen’s lead product candidate, mirvetuximab soravtansine, is being
advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian
cancer, and is in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen’s ADC technology is used in Roche’s
marketed product, Kadcyla^®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by partners
Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of
the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005055/en/